The present invention relates to an enzyme having a NMDA antagonist activity and/or an anticholinergic activity, wherein said enzyme is selected from the group comprising phosphotriesterases and phosphotriesterases derivatives. The present invention also relates to a method for treating a disease, disorder or condition of the central nervous system in a subject, wherein said method comprises administering to the subject an enzyme of the invention.
